Jiantao Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiantao Sun has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jiemei Yang
Department of Cardiology, the First Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, People's Republic of China
1 shared publication - Jing Chi
Department of Cardiology, the First Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, People's Republic of China
1 shared publication - Nan Lv
Second Affiliated Hospital of Harbin Medical University
1 shared publication - Xue Ding
Department of Cardiology, the First Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 4 December 2018
- Published by Springer Nature in Human Genomics
- Vol. 12 (1) , 52
Identification of drug repurposing candidates based on a miRNA-mediated drug and pathway network for cardiac hypertrophy and acute myocardial infarction
Cardiac hypertrophy and acute myocardial infarction (AMI) are two common heart diseases worldwide. However, research is needed into the exact pathogenesis and effective treatment strategies for these diseases. Recently, microRNAs (miRNAs) have been suggested to regulate the pathological pathways of heart disease, indicating a potential role in novel treatments. In our study, we constructed a miRNA-gene-drug network and analyzed its topological features. We also identified some significantly dysregulated miRNA-gene-drug triplets (MGDTs) in cardiac hypertrophy and AMI using a computational method. Then, we characterized the activity score profile features for MGDTs in cardiac hypertrophy and AMI. The functional analyses suggested that the genes in the network held special functions. We extracted an insulin-like growth factor 1 receptor-related subnetwork in cardiac hypertrophy and a vascular endothelial growth factor A-related subnetwork in AMI. Finally, we considered insulin-like growth factor 1 receptor and vascular endothelial growth factor A as two candidate drug targets by utilizing the cardiac hypertrophy and AMI pathways. These results provide novel insights into the mechanisms and treatment of cardiac hypertrophy and AMI.
- 4 December 2018
- Published by Springer Nature in Human Genomics
- Vol. 12 (1) , 52
Open AccessIdentification of drug repurposing candidates based on a miRNA-mediated drug and pathway network for cardiac hypertrophy and acute myocardial infarction
Cardiac hypertrophy and acute myocardial infarction (AMI) are two common heart diseases worldwide. However, research is needed into the exact pathogenesis and effective treatment strategies for these diseases. Recently, microRNAs (miRNAs) have been suggested to regulate the pathological pathways of heart disease, indicating a potential role in novel treatments. In our study, we constructed a miRNA-gene-drug network and analyzed its topological features. We also identified some significantly dysregulated miRNA-gene-drug triplets (MGDTs) in cardiac hypertrophy and AMI using a computational method. Then, we characterized the activity score profile features for MGDTs in cardiac hypertrophy and AMI. The functional analyses suggested that the genes in the network held special functions. We extracted an insulin-like growth factor 1 receptor-related subnetwork in cardiac hypertrophy and a vascular endothelial growth factor A-related subnetwork in AMI. Finally, we considered insulin-like growth factor 1 receptor and vascular endothelial growth factor A as two candidate drug targets by utilizing the cardiac hypertrophy and AMI pathways. These results provide novel insights into the mechanisms and treatment of cardiac hypertrophy and AMI.